Patents Assigned to Changzhou Pharmaceutical Factory
-
Patent number: 10258574Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.Type: GrantFiled: September 8, 2015Date of Patent: April 16, 2019Assignees: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.Inventors: Xuezhi Yin, Linda Sharon Daintree, Sheng Ding, Daniel Mark Ledger, Bing Wang, Wenwen Zhao, Wei Wu, Jiansheng Han
-
Publication number: 20180263912Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.Type: ApplicationFiled: September 8, 2015Publication date: September 20, 2018Applicants: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.Inventors: Xuezhi YIN, Linda Sharon DAINTREE, Sheng DING, Daniel Mark LEDGER, Bing WANG, Wenwen ZHAO, Wei WU, Jiansheng HAN
-
Patent number: 8765947Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.Type: GrantFiled: March 5, 2013Date of Patent: July 1, 2014Assignee: Changzhou Pharmaceutical FactoryInventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
-
Patent number: 8653265Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.Type: GrantFiled: May 27, 2009Date of Patent: February 18, 2014Assignee: Changzhou Pharmaceutical FactoryInventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
-
Publication number: 20130231509Abstract: Disclosed are methods for preparation of two pharmaceutical intermediates (I, II) of Aliskiren, said intermediates are obtained by reacting compound of formula I or II and tribromophosphorus oxide. The method replaces the method in the prior art which is using column chromatopraphy to produce the compounds I and II, and overcomes the defect that the method in the prior art hardly carry out in a large-scale industrial production. The product can be purified by recrystallization or vacuum distillation, and the chemical purity of the product is good.Type: ApplicationFiled: June 16, 2011Publication date: September 5, 2013Applicant: CHANGZHOU PHARMACEUTICAL FACTORYInventors: Xuezhi Yin, Bing Wang, Ying Ji, Mingyuan Liu
-
Publication number: 20130197224Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.Type: ApplicationFiled: March 5, 2013Publication date: August 1, 2013Applicant: CHANGZHOU PHARMACEUTICAL FACTORYInventor: Changzhou Pharmaceutical Factory
-
Publication number: 20110124864Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.Type: ApplicationFiled: May 27, 2009Publication date: May 26, 2011Applicant: CHANGZHOU PHARMACEUTICAL FACTORYInventor: Benshun Chen
-
Patent number: 7608587Abstract: The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents Gly or deletion, X5 represents Arg or deletion. Additionally, the present invention relates to a method for the Exendin 4 polypeptide fragment preparation.Type: GrantFiled: August 1, 2006Date of Patent: October 27, 2009Assignee: Changzhou Pharmaceutical FactoryInventors: Xiaopeng Ma, Bing Wang, Shaoqi Xi